The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Follow along for live updates on stocks, bonds and markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.
Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig ...
Novo Nordisk A/S expects sales to surge again this year as the Danish drugmaker builds supply for blockbuster diabetes ...
As we mentioned on Tuesday, the majority of companies on the S&P 500 that have reported earnings, have beaten estimates, and ...
Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results